Mechanisms of Bortezomib-induced Peripheral Neuropathy
Mechanisms of Bortezomib-induced Peripheral Neuropathy
批准号:
8350911
负责人:
Nathan P Staff
金额:
$14.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-04 至 2017-06-30
关键词:
Adverse effectsAxonal TransportBiologicalBortezomibCancer PatientCellsCellular biologyChronicClinicalConsensus WorkshopDataDevelopmentDevelopment PlansDiseaseDisease modelDistalDoctor of MedicineDoctor of PhilosophyElectrophysiology (science)FoundationsFunctional disorderGated Ion ChannelGoalsImpairmentIn VitroIncidenceInstitutionInvestigationIon ChannelKineticsKnowledgeLinkMalignant NeoplasmsMediatingMentorsMentorshipMicrotubulesMitochondriaMolecular NeurobiologyNeurologistNeurologyNeuropathyNeuroprotective AgentsPainPatch-Clamp TechniquesPathway interactionsPatientsPeripheral NervesPeripheral Nervous System DiseasesPharmaceutical PreparationsPhysiciansPhysiologicalPreventionPrevention strategyProcessPropertyQuality of lifeResearchResearch PersonnelResearch ProposalsRiskRodentScientistSodium ChannelSpinal GangliaStructureSystemTechniquesTestingTrainingUbiquitinUbiquitinationVelcadeaxonal degenerationbasecancer cellcareercareer developmentcell killingcell motilitychemotherapeutic agentchemotherapycostdosageganglion cellinhibitor/antagonistmulticatalytic endopeptidase complexneuromuscularneuronal excitabilityneurophysiologypainful neuropathypatch clamppreventresearch studyskillsvoltage
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side-effect arising in ~400,000 cancer patients yearly and often limits chemotherapy dosage. Pain and other quality of life impairments caused by CIPN are increasing as many forms of cancer become chronic conditions, with an estimated annual cost of ~$2.5 billion dollars (NCI Directors Consensus Workshop, June 2011). It has been assumed that as target-specific therapies were discovered, the off-target effect of peripheral neuropathy would lessen. However, as specific mechanism-based therapies (e.g. proteasome and Jak-2 inhibitors) have been introduced, the incidence of painful, chronic neuropathy has persisted at 30-40% of treated patients. Approaches to limit the impact of CIPN include prevention and symptomatic treatment of neuropathic pain. Preventive strategies are complicated by the risk that protection from CIPN may reduce the primary cancer cell killing effect of a drug. Symptomatic treatments for pain are frequently not successful, reflecting a lack of understanding of the underpinnings of neuropathic pain. In this application, the candidate proposes a comprehensive strategy to understand the biological mechanisms of CIPN caused by a specific chemotherapeutic drug (bortezomib) and the physiologic mechanisms underlying pain caused by the drug. The studies are expected to have broader implications for other diseases of the peripheral nervous system. The candidate is an M.D./Ph.D.-trained neurologist with advanced clinical training in peripheral nerve disorders whose career goal is to perform mechanistic and translational investigations of peripheral nerve disorders and neuropathic pain. Chemotherapy-induced peripheral neuropathy will be used as the model disease system to achieve this goal. The career development plan will be mentored by Dr. Anthony Windebank, a neuromuscular physician-scientist with expertise in CIPN, and Dr. Gianrico Farrugia whose lab focuses on structure-function studies of voltage-gated ion channels. The career development plan combines the strengths of the candidate, the mentors, and the research institution in order to provide an opportunity for the candidate to become a successful independent investigator of peripheral nerve disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Mayo Clinic NeuroNEXT Clinical Research Site
-
批准号:10743328
-
项目类别:
-
资助金额:$46.93万
-
财政年份:2023
-
负责人:Nathan P Staff
-
依托单位:
PHLPP inhibition and Osteoarthritis-Associated Pain
-
批准号:10581073
-
项目类别:
-
资助金额:$20.99万
-
财政年份:2023
-
负责人:Nathan P Staff
-
依托单位:
Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity
-
批准号:10559108
-
项目类别:
-
资助金额:$57.94万
-
财政年份:2023
-
负责人:Nathan P Staff
-
依托单位:
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology
-
批准号:9763518
-
项目类别:
-
资助金额:$35.28万
-
财政年份:2017
-
负责人:Nathan P Staff
-
依托单位:
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-derived iPSC Technology
-
批准号:9450944
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2017
-
负责人:Nathan P Staff
-
依托单位:
Mechanisms of Bortezomib-induced Peripheral Neuropathy
-
批准号:9093719
-
项目类别:
-
资助金额:$14.44万
-
财政年份:2012
-
负责人:Nathan P Staff
-
依托单位:
Mechanisms of Bortezomib-induced Peripheral Neuropathy
-
批准号:8677584
-
项目类别:
-
资助金额:$14.44万
-
财政年份:2012
-
负责人:Nathan P Staff
-
依托单位:
Mechanisms of Bortezomib-induced Peripheral Neuropathy
-
批准号:8505004
-
项目类别:
-
资助金额:$14.44万
-
财政年份:2012
-
负责人:Nathan P Staff
-
依托单位:
Dopaminergic modulation of CA1 intrinsic excitability
-
批准号:6719028
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2002
-
负责人:Nathan P Staff
-
依托单位:
Dopaminergic modulation of CA1 intrinsic excitability
-
批准号:6634372
-
项目类别:
-
资助金额:$5.3万
-
财政年份:2002
-
负责人:Nathan P Staff
-
依托单位:
海外基金